146 related articles for article (PubMed ID: 4085966)
21. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects.
Stegnar M; Mavri A
Thromb Haemost; 1995 Mar; 73(3):453-7. PubMed ID: 7667828
[TBL] [Abstract][Full Text] [Related]
22. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
23. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis.
Francis RB; McGehee WG; Feinstein DI
Thromb Haemost; 1988 Jun; 59(3):412-4. PubMed ID: 3142079
[TBL] [Abstract][Full Text] [Related]
24. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
25. Tissue-type plasminogen activator in patients with intracranial meningiomas.
Tsuda H; Oka K; Noutsuka Y; Sueishi K
Thromb Haemost; 1988 Dec; 60(3):508-13. PubMed ID: 3149049
[TBL] [Abstract][Full Text] [Related]
26. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
27. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
28. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
29. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
30. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
31. Demonstration of a functionally active tPA-like plasminogen activator in human platelets.
Wang DL; Pan YT; Wang JJ; Cheng CH; Liu CY
Thromb Haemost; 1994 Apr; 71(4):493-8. PubMed ID: 8052969
[TBL] [Abstract][Full Text] [Related]
32. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA.
Holvoet P; Cleemput H; Collen D
Thromb Haemost; 1985 Oct; 54(3):684-7. PubMed ID: 3937265
[TBL] [Abstract][Full Text] [Related]
33. Prospective double-arm study of fibrinolysis in surgical patients.
Kosir MA; Schmittinger L; Barno-Winarski L; Duddella P; Pone M; Perales A; Lange P; Brish LK; McGee K; Beleski K; Pawlak J; Mammen E; Sajahan NP; Kozol RA
J Surg Res; 1998 Jan; 74(1):96-101. PubMed ID: 9536981
[TBL] [Abstract][Full Text] [Related]
34. Fibrinolysis after application of a pneumatic tourniquet.
Petäjä J; Myllynen P; Myllylä G; Vahtera E
Acta Chir Scand; 1987; 153(11-12):647-51. PubMed ID: 3124428
[TBL] [Abstract][Full Text] [Related]
35. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
van Giezen JJ; Boon GI; Jansen JW; Bouma BN
Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
[TBL] [Abstract][Full Text] [Related]
36. Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma.
Brommer EJ; Verheijen JH; Chang GT; Rijken DC
Thromb Haemost; 1984 Oct; 52(2):154-6. PubMed ID: 6441302
[TBL] [Abstract][Full Text] [Related]
37. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
[TBL] [Abstract][Full Text] [Related]
38. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
39. Influence of homocysteine on fibrin network lysis.
Lauricella AM; Quintana I; Castañon M; Sassetti B; Kordich L
Blood Coagul Fibrinolysis; 2006 Apr; 17(3):181-6. PubMed ID: 16575255
[TBL] [Abstract][Full Text] [Related]
40. Characterization of plasminogen activator produced by an established cell line from human ovary.
Matsuo C; Fukao H; Matsuo O
J Cell Physiol; 1988 Feb; 134(2):253-60. PubMed ID: 3126195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
